Keywords: oxford, biomedica, licenses, lentivector, pfizer, uk, gene-therapy
Oxford BioMedica licenses LentiVector to Pfizer
Article | 13 June 2005
UK gene-therapy firm Oxford BioMedica has signed a licence agreement for its LentiVector gene-delivery technology with Pfizer, providing the world's ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
